Clinical Trial Update: Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms [Phase 1]

View source ↗

Summary

Termination of a Phase 1 trial evaluating oral azacitidine (CC-486) in Japanese subjects with hematological neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CC-486 (azacitidine)

Snippet

Sponsor: Celgene Corporation | Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 1 | Status: TERMINATED